HSBC Holdings
AVIR icon

HSBC Holdings’s Atea Pharmaceuticals AVIR Stock Holding History

HSBC Holdings’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Sell
221,009
-37,980
-15% -$189K ﹤0.01% 1929
2026
Q1 		$1.38M Buy
258,989
+17,715
+7% +$81.4K ﹤0.01% 1701
2025
Q4 		$855K Buy
241,274
+34,915
+17% +$111K ﹤0.01% 2028
2025
Q3 		$590K Buy
206,359
+10,577
+5% +$36.1K ﹤0.01% 2022
2025
Q2 		$719K Sell
195,782
-5,451
-3% -$16.3K ﹤0.01% 1969
2025
Q1 		$604K Buy
201,233
+39,023
+24% +$122K ﹤0.01% 1991
2024
Q4 		$546K Buy
162,210
+2,610
+2% +$8.67K ﹤0.01% 2125
2024
Q3 		$539K Buy
159,600
+1,491
+0.9% +$5.41K ﹤0.01% 1977
2024
Q2 		$518K Sell
158,109
-13,259
-8% -$49.4K ﹤0.01% 1953
2024
Q1 		$692K Sell
171,368
-9,003
-5% -$35.2K ﹤0.01% 1941
2023
Q4 		$554K Buy
180,371
+168,273
+1,391% +$510K ﹤0.01% 2011
2023
Q3 		$36K Buy
+12,098
New +$41.2K ﹤0.01% 2654
2022
Q2 		– Sell
-11,717
Closed -$83K – 3231
2022
Q1 		$83K Hold
11,717
– – ﹤0.01% 3151
2021
Q4 		$105K Buy
+11,717
New +$183K ﹤0.01% 3135

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HSBC Holdings's AVIR Position: Q2 2026 in Review

HSBC Holdings reduced its Atea Pharmaceuticals (AVIR) stake by 15% in Q2 2026, selling an estimated $189K and leaving 221,009 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1929.

HSBC Holdings first reported a position in AVIR in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.38M in Q1 2026. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • HSBC Holdings held 221,009 shares of Atea Pharmaceuticals worth $1.02M as of Q2 2026.
  • HSBC Holdings sold 37,980 Atea Pharmaceuticals shares in Q2 2026, an estimated $189K.
  • Atea Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1929 holding.
  • HSBC Holdings first reported a position in Atea Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
  • HSBC Holdings's Atea Pharmaceuticals position peaked at $1.38M in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.